---
title: "Oxford Biomedica (LON:OXB) Reaches New 1-Year High  - Should You Buy?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258353481.md"
description: "Oxford Biomedica (LON:OXB) reached a new 52-week high of GBX 618 ($8.33) during trading, closing at GBX 617 ($8.31). Analysts have mixed opinions, with Peel Hunt maintaining a \"buy\" rating and a price target of GBX 451, while Royal Bank of Canada raised its target to GBX 930. The stock has a consensus rating of \"Moderate Buy\" and a target price of GBX 540.25. Insider trading activity includes purchases and sales by company insiders. The company specializes in cell and gene therapy with over 25 years of experience."
datetime: "2025-09-22T12:10:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258353481.md)
  - [en](https://longbridge.com/en/news/258353481.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258353481.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/258353481.md) | [繁體中文](https://longbridge.com/zh-HK/news/258353481.md)


# Oxford Biomedica (LON:OXB) Reaches New 1-Year High  - Should You Buy?

Oxford Biomedica plc (LON:OXB - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The company traded as high as GBX 618 ($8.33) and last traded at GBX 617 ($8.31), with a volume of 922845 shares traded. The stock had previously closed at GBX 586.71 ($7.90).

Get **Oxford Biomedica** alerts:

## Analysts Set New Price Targets

Several brokerages have recently issued reports on OXB. Peel Hunt reiterated a "buy" rating and issued a GBX 451 price objective on shares of Oxford Biomedica in a research note on Friday, August 1st. Royal Bank Of Canada lifted their price objective on Oxford Biomedica from GBX 800 to GBX 930 and gave the company an "outperform" rating in a report on Tuesday, August 26th. Finally, JPMorgan Chase & Co. cut their price objective on Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 540.25.

**Check Out Our Latest Report on Oxford Biomedica**

## Oxford Biomedica Trading Up 6.3%

The company has a market capitalization of £749.18 million, a PE ratio of -1,493.12 and a beta of 1.09. The business's 50-day simple moving average is GBX 491.64 and its two-hundred day simple moving average is GBX 369.84. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48.

## Insider Activity

In other news, insider Roch Doliveux purchased 67,000 shares of the company's stock in a transaction on Friday, August 15th. The shares were bought at an average price of GBX 450 per share, for a total transaction of £301,500. Also, insider Dame Kay Davies sold 4,563 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of GBX 500, for a total transaction of £22,815. 43.30% of the stock is owned by corporate insiders.

## Oxford Biomedica Company Profile

(Get Free Report)

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

## Further Reading

-   Five stocks we like better than Oxford Biomedica
-   There Are Different Types of Stock To Invest In
-   Lyft Surges on Waymo Robotaxi Deal: Is the Stock a Buy?
-   What is the Nikkei 225 index?
-   GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?
-   Are Penny Stocks a Good Fit for Your Portfolio?
-   3 Overlooked Value Stocks Set to Surge as Rates Drop

_This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._

## Should You Invest $1,000 in Oxford Biomedica Right Now?

Before you consider Oxford Biomedica, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.

While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

## Related News & Research

- [Here's How Much $100 Invested In abrdn Physical Silver Shares ETF 10 Years Ago Would Be Worth Today](https://longbridge.com/en/news/281394387.md)
- [BREAKINGVIEWS-SpaceX IPO will gauge market moxie more than depth](https://longbridge.com/en/news/281406751.md)
- [Palantir vs. Oracle: 1 AI Stock Looks Cheap](https://longbridge.com/en/news/281400403.md)
- [BUZZ-Rosenblatt says finding partner for Snap's smart glasses unit tough](https://longbridge.com/en/news/281357569.md)
- [BUZZ-Street View: Nike's turnaround remains work in progress](https://longbridge.com/en/news/281331333.md)